2014 Fiscal Year Final Research Report
Arthritis-inhibiting effects of sunitinib and sorafenib, inhibitors of vascular endothelial growth factor receptor tyrosine kinase.
| Project/Area Number |
23591448
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
FURUYA Kazuhiro 東京慈恵会医科大学, リウマチ膠原病内科, 助教
KAKU Ying 東京慈恵会医科大学, リウマチ膠原病内科, 研究技術職
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Keywords | 関節炎 / 関節リウマチ / スニチニブ / 血管新生 / 血管内皮増殖因子 / チロシンキナーゼ阻害剤 |
|---|
| Outline of Final Research Achievements |
We confirmed the inhibitory effects of sunitinib, a inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on murine arthritis model.
Sunitinib at a concentration of 0, 30 or 60mg/kg/day was intraperitoneally administrated to mice with collagen-induced arthritis. We compared the changes in arthritis score over time, pathological score, microvascular density in synovial membrane between the vehicle and treatment groups.
In the sunitinib-treated groups, the arthritis score decreased in a dose-dependent manner in comparison with that in the vehicle group. Futhermore, improvement in the pathological score, and a decrease in the synovial microvascular density were also observed in the sunitinib-treated groups.
|
| Free Research Field |
リウマチ膠原病内科学
|
